Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $5.3 million.

  • Amphastar Pharmaceuticals' Capital Expenditures fell 6122.67% to $5.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.0 million, marking a year-over-year increase of 249.26%. This contributed to the annual value of $41.0 million for FY2024, which is 753.29% up from last year.
  • Per Amphastar Pharmaceuticals' latest filing, its Capital Expenditures stood at $5.3 million for Q3 2025, which was down 6122.67% from $10.6 million recorded in Q2 2025.
  • In the past 5 years, Amphastar Pharmaceuticals' Capital Expenditures registered a high of $13.8 million during Q3 2024, and its lowest value of $5.3 million during Q3 2025.
  • Over the past 5 years, Amphastar Pharmaceuticals' median Capital Expenditures value was $7.6 million (recorded in 2021), while the average stood at $8.3 million.
  • As far as peak fluctuations go, Amphastar Pharmaceuticals' Capital Expenditures skyrocketed by 8127.33% in 2023, and later crashed by 6122.67% in 2025.
  • Over the past 5 years, Amphastar Pharmaceuticals' Capital Expenditures (Quarter) stood at $6.9 million in 2021, then dropped by 8.26% to $6.3 million in 2022, then surged by 49.64% to $9.4 million in 2023, then skyrocketed by 31.44% to $12.4 million in 2024, then tumbled by 56.91% to $5.3 million in 2025.
  • Its Capital Expenditures was $5.3 million in Q3 2025, compared to $10.6 million in Q2 2025 and $10.7 million in Q1 2025.